{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:59:05Z","timestamp":1777557545277,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>\n                    The aim of this study was to establish the effects of clinical doses of Gla-300 versus Gla-100 on suppression of glucagon, lipolysis, and ketogenesis in type 1 diabetes mellitus (T1DM). Eighteen persons with T1DM (age 40\u2009\u00b1\u200912 years, diabetes duration 26\u2009\u00b1\u200912 years, body mass index 23.4\u2009\u00b1\u20092\u2009kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , A1C 7.19%\u2009\u00b1\u20090.52% [55\u2009\u00b1\u20096\u2009mmol\/mol]) were studied after 3 months of titration with Gla-300 and Gla-100 (randomized, crossover design) with a 24-h euglycemic clamp (s.c. injection of individual insulin daily doses used by subjects for previous 2 weeks, Gla-300 0.35\u2009\u00b1\u20090.08 and Gla-100 0.28\u2009\u00b1\u20090.07\u2009U\/kg). Gla-300 resulted in (1) less increase in insulin concentration for 0\u201312\u2009h, but greater insulin concentration in 12\u201324\u2009h (no differences for 24\u2009h); (2) greater glucagon suppression; (3) greater prehepatic insulin-to-glucagon molar ratio, primarily in 12\u201324\u2009h (ratio 1.78, 90% confidence intervals [CIs] 1.5\u20132.1); and (4) lower 24-h free fatty acid (0.81; 90% CI 0.73\u20130.89), glycerol (0.78; 90% CI 0.65\u20130.94), and \u03b2-hydroxybutyrate (0.72; 90% CI 0.58\u20130.90). Over the 24\u2009h postinjection, as compared with Gla-100, clinical doses of Gla-300 exhibit greater suppressive effects on glucagon, lipolysis, and ketogenesis, whereas the effects on glucose metabolism are equivalent.\n                  <\/jats:p>","DOI":"10.1089\/dia.2019.0231","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T10:09:59Z","timestamp":1565777399000},"page":"57-61","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus"],"prefix":"10.1177","volume":"22","author":[{"given":"Paola","family":"Lucidi","sequence":"first","affiliation":[{"name":"Section of Endocrinology &amp; Metabolism, Department of Medicine, Perugia University School of Medicine, Perugia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Porcellati","sequence":"additional","affiliation":[{"name":"Section of Endocrinology &amp; Metabolism, Department of Medicine, Perugia University School of Medicine, Perugia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Cioli","sequence":"additional","affiliation":[{"name":"Section of Endocrinology &amp; Metabolism, Department of Medicine, Perugia University School of Medicine, Perugia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Candeloro","sequence":"additional","affiliation":[{"name":"Section of Endocrinology &amp; Metabolism, Department of Medicine, Perugia University School of Medicine, Perugia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Marinelli Andreoli","sequence":"additional","affiliation":[{"name":"Section of Endocrinology &amp; Metabolism, Department of Medicine, Perugia University School of Medicine, Perugia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geremia B.","family":"Bolli","sequence":"additional","affiliation":[{"name":"Section of Endocrinology &amp; Metabolism, Department of Medicine, Perugia University School of Medicine, Perugia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine G.","family":"Fanelli","sequence":"additional","affiliation":[{"name":"Section of Endocrinology &amp; Metabolism, Department of Medicine, Perugia University School of Medicine, Perugia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12415"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0006"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0706"},{"key":"e_1_3_6_5_2","first-page":"2000","volume-title":"Glucagon physiologyEndotext","author":"Gosmanov NR","unstructured":"Gosmanov NR, , Gosmanov AR, , Gerich JE: Glucagon physiology. In: De Groot LJ, , Chrousos G, , Dungan K, , Feingold KR, , Grossman A, , Hershman JM, , Koch C, , Korbonits M, , McLachlan R, , New M, , Purnell J, , Rebar R, , Singer F, , Vinik A, eds. Endotext [Internet]. South Dartmouth, MA: MDText.com, Inc., 2000\u20132011."},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.35.12.1326"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115384"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1112"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0002"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115809"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2000.00085.x"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13048"},{"key":"e_1_3_6_14_2","first-page":"A","article-title":"Insulin glargine 300\u2009U\/ml and insulin glargine 100\u2009U\/ml show equipotent in vivo blood glucose lowering when administered intravenously in dogs (abstract)","volume":"18","author":"Werner U","year":"2016","unstructured":"Werner U, , Korn M, , Tennagels N: Insulin glargine 300\u2009U\/ml and insulin glargine 100\u2009U\/ml show equipotent in vivo blood glucose lowering when administered intravenously in dogs (abstract). Diabetes Technol Ther, 2016; 18:A-119.","journal-title":"Diabetes Technol Ther"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0684"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13751"},{"key":"e_1_3_6_17_2","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03001323 Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis; (Last Update Posted : April 16 2019); Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT03001323"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2019.0231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2019.0231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2019.0231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:18:46Z","timestamp":1777400326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2019.0231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1089\/dia.2019.0231"],"URL":"https:\/\/doi.org\/10.1089\/dia.2019.0231","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}